Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-484-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$310,000.00
Profitability
Miscellaneous
Employees81
OptionableOptionable
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its quarterly earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.16. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
2 Wall Street analysts have issued 12 month price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $15.00 to $16.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $15.50 in the next year. This suggests a possible upside of 91.8% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.
What is the consensus analysts' recommendation for Xenon Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.
Has Xenon Pharmaceuticals been receiving favorable news coverage?
Headlines about XENE stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Radius Health (RDUS), Apellis Pharmaceuticals (APLS), G1 Therapeutics (GTHX), Arvinas (ARVN), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Inflarx (IFRX), Evolus (EOLS), ANI Pharmaceuticals (ANIP), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX), Principia Biopharma (PRNB), Omeros (OMER), Cara Therapeutics (CARA) and Ra Pharmaceuticals (RARX).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Dr. Simon N. Pimstone, CEO & Director (Age 51)
- Mr. Ian C. Mortimer, Pres, CFO, COO & Company Sec. (Age 43)
- Mr. Robin P. Sherrington, Exec. VP of Bus. & Corp. Devel. (Age 58)
- Dr. James R. Empfield, Sr. VP of Drug Discovery of Xenon Pharmaceuticals USA Inc (Age 58)
- Ms. Jodi Regts B.A., MBA, VP of Corp. Affairs & Investor Relations
Who are Xenon Pharmaceuticals' major shareholders?
Xenon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (9.51%), Sphera Funds Management LTD. (1.78%), BlackRock Inc. (1.12%), Granite Point Capital Management L.P. (1.00%), Eversept Partners LP (0.81%) and Two Sigma Investments LP (0.79%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Which institutional investors are selling Xenon Pharmaceuticals stock?
Which institutional investors are buying Xenon Pharmaceuticals stock?
XENE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Two Sigma Investments LP, Altshuler Shaham Ltd, Sphera Funds Management LTD., Millennium Management LLC, Alps Advisors Inc. and Two Sigma Advisers LP. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $8.08.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $203.94 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
What is Xenon Pharmaceuticals' official website?
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
